Dr. Nuermberger is Professor of Medicine and International Health at Johns Hopkins University. His primary research interest is the experimental chemotherapy of TB. The work uses validated and developmental murine models of active TB and latent TB infection to evaluate the efficacy of promising new antimicrobials. A major goal is to identify new agents that can be used to shorten the duration of TB therapy or allow more intermittent drug administration, including long-acting injectable administration.
Conflict of Interest: Receives research funding from Janssen and Wintermute.